放射性薬物製造会社のPerspective Therapeuticsは、その[212Pb]VMT-α-NETプログラムのデータが2026年のNANETS多分野NET医療シンポジウムで提示されることが承認されました。これは神経内分泌腫瘍の治療に関する継続的な研究を強調しています。
なぜ重要か. 投資家および医療専門家は、神経内分泌腫瘍に対する[212Pb]VMT-α-NET治療の効果と安全性について洞察を得ることができます。
The Company has proprietary technology that utilizes the alpha-generating isotope <sup>212</sup>Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).
The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary <sup>224</sup>Ra/<sup>212</sup>Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candi…
SEATTLE, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that d…
Perspective designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion s…
